GO:0051898 negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051898 describes any process that stops, prevents, or reduces PI3K/AKT signal transduction, a central growth and survival pathway.
• Negative regulation is achieved by phosphatases such as PTEN, by protein kinase C (PKC)-mediated feedback, and by pharmacological inhibitors.
• Loss of negative regulation leads to constitutive AKT activation, which drives cancer, metabolic disorders, and neurodegeneration.
• The term is studied using knockout, point-mutation, knock-in, and overexpression cell models, combined with phospho-proteomics and imaging.
• Key experimental readouts include AKT phosphorylation at Thr308/Ser473, downstream targets like GSK3β, and phenotypic assays for proliferation and apoptosis.
• CRISPR-based screens and bioinformatics can identify novel negative regulators and predict pathway rewiring in disease.
Description
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling cascade is a master regulator of cell growth, survival, metabolism, and motility. GO:0051898, negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction, encompasses all molecular events that attenuate this cascade, ensuring that PI3K/AKT activity is transient and context-appropriate. Dysregulation of these negative feedback mechanisms is a hallmark of many human diseases, including cancer, where loss of PTEN or constitutive AKT activation promotes tumorigenesis. Understanding how this negative regulation is achieved and how it can be experimentally manipulated is therefore critical for both basic research and therapeutic development. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease links, and CRISPR-based methods used to study GO:0051898.
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction At A Glance
| GO ID | GO:0051898 |
|---|---|
| GO term | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| Ontology | biological_process |
| Synonym | negative regulation of PI3K/Akt signal transduction; negative regulation of AKT signaling cascade; inhibition of protein kinase B signaling cascade |
| Major function | Attenuation of PI3K/AKT signaling to control cell growth, survival, and metabolism |
| Key negative regulators | PTEN, PKC isoforms, and pharmacological inhibitors |
| Associated diseases | Cancer, neurodegeneration, metabolic disorders |
| Experimental models | Knockout, point-mutation, knock-in, overexpression cell lines |
What Is GO:0051898?
GO:0051898 is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction. In other words, it covers the cellular strategies that put the brakes on PI3K/AKT signaling, including dephosphorylation of key lipid and protein substrates, degradation of signaling components, and feedback inhibition from downstream kinases.
Why Is negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Important in Cell Biology?
Negative regulation of PI3K/AKT signaling is essential for normal development and tissue homeostasis. When this regulation fails, cells can acquire uncontrolled proliferation, resistance to apoptosis, and altered metabolism, which are hallmarks of cancer and other diseases. Moreover, many viruses and pathogens manipulate this negative regulation to evade immune responses. Thus, understanding GO:0051898 provides insights into fundamental cell biology and offers targets for therapeutic intervention.
• Prevents excessive PI3K/AKT activity that could lead to oncogenic transformation.
• Controls immune cell activation and cytokine production, as shown in IL-5/GM-CSF signaling.
• Modulates neuronal survival and tau phosphorylation, linking to neurodegeneration.
• Influences angiogenesis and vascular homeostasis, relevant to thrombosis and cardiovascular disease.
• Regulates microglial neuroinflammation and cognitive function.
• Provides a mechanism for viral interference with host signaling.
• Serves as a target for anticancer drugs and nanotherapeutics.
• Enables feedback control from downstream kinases like PKC.
• Helps maintain metabolic balance through insulin signaling.
• Is a focus of CRISPR screens to identify novel regulators.
What Happens During negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction?
Dephosphorylation of PIP3 by PTEN
In simple terms: PTEN acts like a brake by removing phosphate groups from PIP3, a lipid that recruits AKT to the membrane.
The tumor suppressor PTEN is a lipid phosphatase that converts phosphatidylinositol-3,4,5-trisphosphate (PIP3) back to phosphatidylinositol-4,5-bisphosphate (PIP2), thereby preventing AKT membrane recruitment and activation. Loss of PTEN function is a common event in colorectal cancers and many other malignancies, leading to constitutive PI3K/AKT signaling.
Feedback inhibition by protein kinase C (PKC)
In simple terms: PKC can turn off the PI3K/AKT pathway by phosphorylating components of the cascade.
PKC isoforms negatively regulate PI3K and AKT signaling, as demonstrated in studies showing that PKC activation reduces AKT phosphorylation and downstream signaling. This feedback mechanism helps terminate growth factor signals and prevents sustained pathway activation.
Degradation of signaling intermediates
In simple terms: Cells can destroy key proteins in the pathway to shut it down.
Ubiquitin-proteasome-mediated degradation of PI3K subunits or AKT itself can contribute to negative regulation. While specific E3 ligases are not detailed in the provided citations, this general mechanism is part of the cellular toolkit for attenuating signaling.
Pharmacological and nanomaterial-induced inhibition
In simple terms: Certain drugs or nanoparticles can block the pathway, mimicking natural negative regulation.
Hydroxyapatite nanospheres have been shown to exert antitumor effects by activating mitochondria-dependent apoptosis and negatively regulating the PI3K/AKT pathway. Similarly, natural compounds like Huoxue Jiedu decoction modulate the PI3K/AKT/NF-κB axis in deep vein thrombosis.
Viral interference with PI3K/AKT negative regulation
In simple terms: Some viruses disrupt the brakes on PI3K/AKT to promote their own replication.
Negative-stranded RNA viruses can manipulate the PI3K/AKT pathway, often by interfering with negative regulators, to enhance viral replication and evade host immunity.
Key Genes Involved in GO:0051898 negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
The following genes and proteins are central to the negative regulation of PI3K/AKT signaling, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTEN | Lipid phosphatase that dephosphorylates PIP3 | Tumor suppressor frequently mutated in cancers |
| PKC (e.g., PRKCA, PRKCB) | Phosphorylates and inhibits PI3K/AKT components | Feedback regulation of growth factor signaling |
| AKT1 | Serine/threonine kinase; target of negative regulation | Readout of pathway activity; mutations in cancer |
| PIK3CA | Catalytic subunit of PI3K; subject to negative regulation | Oncogene; mutations activate pathway |
| GSK3B | Downstream target of AKT; involved in tau phosphorylation | Neurodegeneration and metabolism |
| IL5RA | Receptor for IL-5; activates PI3K/AKT | Regulation by cytokines in hematopoietic cells |
| CSF2RB | Common beta chain for GM-CSF/IL-3/IL-5 receptors | Cytokine signaling and negative feedback |
| NFKB1 | Transcription factor downstream of PI3K/AKT | Inflammation and thrombosis |
| TSC1/TSC2 | Tumor suppressors upstream of mTOR | Integration of PI3K/AKT signals |
| FOXO1 | Transcription factor inhibited by AKT | Cell survival and metabolism |
| MTOR | Kinase downstream of AKT | Central regulator of growth |
| PTK2 (FAK) | Focal adhesion kinase; crosstalk with PI3K | Cell migration and invasion |
| SRC | Non-receptor tyrosine kinase; modulates PI3K | Cancer progression |
| PDPK1 | Phosphorylates AKT at Thr308 | Essential for AKT activation |
| RICTOR | Component of mTORC2; phosphorylates AKT Ser473 | AKT activation |
| PHLPP1/2 | Phosphatases that dephosphorylate AKT | Direct negative regulation |
| PPP2CA | Protein phosphatase 2A; dephosphorylates AKT | Negative regulation |
| INPP4B | Lipid phosphatase; degrades PIP3 | Tumor suppressor |
How Is negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Regulated?
The negative regulation of PI3K/AKT signaling is itself tightly controlled. Feedback loops from downstream effectors such as mTORC1 and S6K can phosphorylate IRS-1, reducing PI3K activation. PKC-mediated phosphorylation provides another layer of inhibition. Additionally, PTEN expression and activity are regulated by transcription factors, microRNAs, and post-translational modifications. In disease states, these regulatory mechanisms are often disrupted, leading to pathway hyperactivation.
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Colorectal cancer, Cowden syndrome | PTEN knockout HCT116 cells |
| AKT1 | Cancer, metabolic disorders | AKT1 point-mutation knock-in |
| GSK3B | Alzheimer's disease, tauopathy | GSK3B overexpression in neurons |
| NFKB1 | Deep vein thrombosis, inflammation | NFKB1 knockout endothelial cells |
| IL5RA | Asthma, eosinophilia | IL5RA knockout hematopoietic cells |
Cancer
Loss of negative regulation of PI3K/AKT signaling is a hallmark of many cancers. PTEN mutations or deletions lead to constitutive AKT activation, promoting cell survival, proliferation, and metastasis. Targeting PTEN-deficient tumors with PI3K/AKT inhibitors is an active area of research.
Neurodegeneration
Androgens regulate tau phosphorylation through the PI3K/AKT/GSK3β axis, and disruption of this negative regulation contributes to tauopathies such as Alzheimer's disease. Microglia-mediated neuroinflammation also involves PI3K signaling, and its negative regulation may protect against cognitive dysfunction.
Vascular and inflammatory diseases
The PI3K/AKT/NF-κB pathway is implicated in deep vein thrombosis, and negative regulation by compounds like Huoxue Jiedu decoction can ameliorate thrombosis. Similarly, dysregulated PI3K signaling in immune cells can lead to chronic inflammation.
Viral infections
Negative-stranded RNA viruses often manipulate the PI3K/AKT pathway to enhance replication. Understanding how viruses interfere with negative regulation may reveal antiviral targets.
From negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTEN activate PI3K/AKT? | PTEN knockout cell line (e.g., HCT116) |
| Does a specific AKT mutation affect negative regulation? | AKT1 point-mutation knock-in |
| Can a candidate gene inhibit PI3K/AKT? | Overexpression of candidate gene |
| How does a drug affect pathway activity? | Wild-type cells treated with inhibitor |
| What is the role of PKC in feedback inhibition? | PKC knockout or knockdown |
| Does a viral protein interfere with negative regulation? | Viral infection of knockout cells |
How to Study the negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phospho-AKT levels | Drug treatment validation |
| Phospho-proteomics | Global phosphorylation changes | Pathway profiling |
| CRISPR knockout screen | Gene essentiality for pathway activity | Novel regulator discovery |
| RNA-seq | Transcriptional changes | Feedback gene expression |
| Immunofluorescence | Subcellular localization of AKT | Activation state |
| Co-immunoprecipitation | Protein-protein interactions | Complex formation |
| Luciferase reporter | NF-κB or FOXO activity | Downstream readout |
Phospho-proteomics
Mass spectrometry-based phospho-proteomics can quantify changes in AKT phosphorylation at Thr308 and Ser473, as well as downstream targets like GSK3β, providing a global view of pathway activity.
Western blotting
Immunoblotting with phospho-specific antibodies is a standard method to assess PI3K/AKT negative regulation, as used in studies of PKC-mediated inhibition and nanosphere treatment.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of PI3K/AKT signaling. Such screens have been used to uncover mechanisms of viral interference and drug resistance.
Live-cell imaging
Fluorescent reporters for AKT activity (e.g., AKT biosensors) allow real-time monitoring of negative regulation dynamics in living cells.
How CRISPR Can Be Used to Study GO:0051898 negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
Knockout
CRISPR knockout of negative regulators such as PTEN or PKC isoforms can constitutively activate PI3K/AKT signaling, providing a model to study pathway hyperactivation and test inhibitors.
Point Mutation
Introducing point mutations in AKT1 (e.g., E17K) or PIK3CA (e.g., H1047R) via CRISPR can mimic oncogenic activation and reveal how negative regulation is bypassed.
Knock-in
Knock-in of tagged AKT or PTEN allows for live-cell imaging and proteomic analysis of negative regulation dynamics.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression of candidate negative regulators can suppress PI3K/AKT signaling, enabling functional validation.
How EDITGENE Supports negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction Research
Researchers studying negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway attenuation, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction research.
Frequently Asked Questions About negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
What is GO:0051898?
GO:0051898 is the Gene Ontology term for negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction, describing any process that reduces PI3K/AKT signaling.
What genes are involved in negative regulation of PI3K/AKT signaling?
Key genes include PTEN, PKC isoforms, PHLPP1/2, and PPP2CA, among others.
How is PI3K/AKT signaling negatively regulated?
It is negatively regulated by lipid phosphatases like PTEN, protein phosphatases, feedback phosphorylation by PKC, and degradation of signaling components.
Why is negative regulation of PI3K/AKT important in cancer?
Loss of negative regulation leads to constitutive AKT activation, driving tumor growth and survival; PTEN is a major tumor suppressor.
What experimental models are used to study GO:0051898?
Knockout, point-mutation, knock-in, and overexpression cell models, often combined with phospho-proteomics and imaging.
Can CRISPR be used to study negative regulation of PI3K/AKT?
Yes, CRISPR knockout, point mutation, knock-in, and activation are powerful tools to dissect this pathway.
What diseases are linked to defective negative regulation of PI3K/AKT?
Cancer, neurodegeneration, vascular thrombosis, and viral infections are linked to dysregulated negative regulation.
How do viruses affect PI3K/AKT negative regulation?
Some viruses manipulate the pathway to enhance replication, often by interfering with negative regulators.
What are the readouts for PI3K/AKT negative regulation?
Phospho-AKT (Thr308/Ser473), phospho-GSK3β, and downstream reporter activity are common readouts.
What services does EDITGENE offer for studying GO:0051898?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics analysis.
Conclusion
GO:0051898 encompasses the critical mechanisms that restrain PI3K/AKT signaling, protecting cells from uncontrolled growth and survival. Dysregulation of these mechanisms underlies numerous diseases, making them attractive therapeutic targets. By leveraging CRISPR-based models and multi-omics approaches, researchers can dissect the precise molecular players and translate these insights into new treatments.
References
- 1. Blanco J et al.. 2020. Phosphatidylinositol-3-kinase-Akt pathway in negative-stranded RNA virus infection: a minireview.. Arch Virol 165(10):2165-2176 PMID: 32740830
- 2. Wen HC et al.. 2003. Negative regulation of phosphatidylinositol 3-kinase and Akt signalling pathway by PKC.. Cell Signal 15(1):37-45 PMID: 12401518
- 3. Kotelevets L et al.. 2018. Targeting PTEN in Colorectal Cancers.. Adv Exp Med Biol 1110:55-73 PMID: 30623366
- 4. Zhao H et al.. 2018. Antitumor Effect by Hydroxyapatite Nanospheres: Activation of Mitochondria-Dependent Apoptosis and Negative Regulation of Phosphatidylinositol-3-Kinase/Protein Kinase B Pathway.. ACS Nano 12(8):7838-7854 PMID: 30059628
- 5. Maziz MNH et al.. 2025. Microglia-Mediated Neuroinflammation Through Phosphatidylinositol 3-Kinase Signaling Causes Cognitive Dysfunction.. Int J Mol Sci 26(15) PMID: 40806341
- 6. Yao M et al.. 2025. Androgens Regulate Tau Phosphorylation Through Phosphatidylinositol 3-Kinase-Protein Kinase B-Glycogen Synthase Kinase 3β Signaling.. Neuroscience 568:503-518 PMID: 35777535
- 7. Wang Y et al.. 2026. Study on the mechanism of Huoxue Jiedu decoction in the intervention of phosphatidylinositol 3-kinase/serine-threonine kinase/nuclear factor-kappa B pathway in the treatment of deep vein thrombosis.. J Ethnopharmacol 355(Pt A):120605 PMID: 40945881
- 8. Dijkers PF et al.. 1999. Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor.. Oncogene 18(22):3334-42 PMID: 10362354
